{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bladder&page=6",
    "query": {
      "condition": "Bladder",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 1852,
    "total_pages": 186,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bladder&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bladder&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T21:32:45.841Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02591199",
      "title": "Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Interstitial Cystitis",
        "Bladder Pain Syndrome"
      ],
      "interventions": [
        {
          "name": "URG101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Lidocaine",
          "type": "DRUG"
        },
        {
          "name": "Heparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Urigen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2015-09",
      "completion_date": "2018-06-18",
      "has_results": true,
      "last_update_posted_date": "2026-02-03",
      "last_synced_at": "2026-10-24T21:32:45.841Z",
      "location_count": 11,
      "location_summary": "Escondido, California • San Diego, California • Cartersville, Georgia + 8 more",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Cartersville",
          "state": "Georgia"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02591199"
    },
    {
      "nct_id": "NCT04734847",
      "title": "Motor Cortical Neuromodulation in Women With Interstitial Cystitis/Bladder Pain Syndrome",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Interstitial Cystitis",
        "Bladder Pain Syndrome"
      ],
      "interventions": [
        {
          "name": "Repetitive Transcranial Magnetic Stimulation (rTMS)",
          "type": "DEVICE"
        },
        {
          "name": "Sham Repetitive Transcranial Magnetic Stimulation (Sham-rTMS)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2021-06-01",
      "completion_date": "2026-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-10-24T21:32:45.841Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04734847"
    },
    {
      "nct_id": "NCT05891171",
      "title": "Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Advanced Malignancies",
        "Bladder Cancer",
        "Cervical Cancer",
        "Esophageal Cancer",
        "Gastric Cancer",
        "Gastroesophageal-junction Cancer (GEJ)",
        "Head and Neck Squamous Cell Carcinoma (HNSCC)",
        "Non-Small Cell Lung Cancer (NSCLC)",
        "Ovarian Cancer",
        "Renal Cell Carcinoma (RCC)",
        "Triple Negative Breast Cancer (TNBC)"
      ],
      "interventions": [
        {
          "name": "AB598",
          "type": "DRUG"
        },
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arcus Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2023-10-13",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-24T21:32:45.841Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Lake City, Florida + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Lake City",
          "state": "Florida"
        },
        {
          "city": "Hinsdale",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05891171"
    },
    {
      "nct_id": "NCT01767519",
      "title": "A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Overactive Bladder",
        "Urinary Incontinence"
      ],
      "interventions": [
        {
          "name": "BOTOX®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "solifenacin",
          "type": "DRUG"
        },
        {
          "name": "Botox placebo (normal saline)",
          "type": "DRUG"
        },
        {
          "name": "solifenacin placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 356,
      "start_date": "2013-03-01",
      "completion_date": "2015-03-18",
      "has_results": true,
      "last_update_posted_date": "2019-04-23",
      "last_synced_at": "2026-10-24T21:32:45.841Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01767519"
    },
    {
      "nct_id": "NCT03311334",
      "title": "A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Renal Cell Carcinoma (RCC)",
        "Urothelial Carcinoma",
        "Primary Peritoneal Cancer",
        "Platinum-resistant Ovarian Cancer (PROC)",
        "Serous Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "DSP-7888 Dosing Emulsion",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2017-12-14",
      "completion_date": "2022-11-29",
      "has_results": true,
      "last_update_posted_date": "2024-04-18",
      "last_synced_at": "2026-10-24T21:32:45.841Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Los Angeles, California • San Francisco, California + 14 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03311334"
    },
    {
      "nct_id": "NCT06161532",
      "title": "Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Carcinoma of the Bladder",
        "Small Cell Carcinoma of the Urinary Tract",
        "Squamous Cell Carcinoma of the Bladder",
        "Squamous Cell Carcinoma of the Urinary Tract",
        "Primary Adenocarcinoma of the Bladder",
        "Primary Adenocarcinoma of the Urinary Tract",
        "Renal Medullary Carcinoma",
        "Squamous Cell Carcinoma of the Penis"
      ],
      "interventions": [
        {
          "name": "Sacituzumab govitecan",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 60,
      "start_date": "2024-08-01",
      "completion_date": "2028-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-10-24T21:32:45.841Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06161532"
    },
    {
      "nct_id": "NCT04566393",
      "title": "Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies",
      "overall_status": "AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Pancreatic Cancer",
        "Small Bowel Cancer",
        "Colorectal Cancer",
        "Melanoma",
        "Non Small Cell Lung Cancer",
        "Thyroid Cancer",
        "Bladder Cancer",
        "Head and Neck Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Cholangiocarcinoma",
        "Ovarian Cancer",
        "Hepatocellular Carcinoma",
        "Glioblastoma",
        "MAPK Gene Mutation",
        "KRAS Activating Mutation",
        "BRAF Gene Mutation",
        "NRAS Gene Mutation",
        "HRAS Gene Mutation",
        "MEK Mutation",
        "ERK Mutation"
      ],
      "interventions": [
        {
          "name": "Ulixertinib (BVD-523)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "xCures",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-10-24T21:32:45.841Z",
      "location_count": 26,
      "location_summary": "Mobile, Alabama • Arroyo Grande, California • Newport Beach, California + 19 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Arroyo Grande",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04566393"
    },
    {
      "nct_id": "NCT03150836",
      "title": "Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Terence Friedlander, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2017-10-01",
      "completion_date": "2024-09-01",
      "has_results": false,
      "last_update_posted_date": "2017-10-19",
      "last_synced_at": "2026-10-24T21:32:45.841Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03150836"
    },
    {
      "nct_id": "NCT06493370",
      "title": "Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Intravenous ascorbic acid/vitamin C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2025-01-16",
      "completion_date": "2030-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-02-20",
      "last_synced_at": "2026-10-24T21:32:45.841Z",
      "location_count": 2,
      "location_summary": "Iowa City, Iowa • Kansas City, Kansas",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06493370"
    },
    {
      "nct_id": "NCT07377929",
      "title": "Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Benign Prostatic Hypertrophy (BPH)",
        "Lower Urinary Track Symptoms"
      ],
      "interventions": [
        {
          "name": "Survey using a questionnaire.",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Benaroya Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2026-01-19",
      "completion_date": "2027-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-30",
      "last_synced_at": "2026-10-24T21:32:45.841Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07377929"
    }
  ]
}